1Karayiannis P. Hepatits B virus:old new and future approaches to antivirul treatment. J Antimicrob Chemother,2003,51 : 765-785.
2King RW, Ladner SK, Miller TJ, et al. Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative,alone and in combination with ( )beta L-2' , 3'-dideoxy-3'-thiacytidine. Antimierob Agents Chemother, 1998,42 : 3179-3186.
3Feld J, Colledge D, Sozzi T, et al. The phenylpropenamide derivative AT-130 inhibits HBV replication at viral encapisdation and packaging.Hepatology,2002,36(part2) : 300A.
4Deres K, Schrode CH, Paessens A, et al. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science, 2003,299 : 893-896.
5Ono-Nita SK, Kato N, Shiratori Y, et al. Novel nucleoside analogue MCC-478(LY582563) is effective against widetype or larnivudine-resistant hepatitis B virus. Antimicrob Agents Chemother, 2002, 46 :2602-2605.
6Shlomai A, Shaul Y. Inhibition of hepatits B virus expression and replication by RNA interference. Hepatology,2003,37 : 764-770.
7Klein C, Bock C T, Wedemeyer H, et al. Inhibition of hepatits B virus replication in vivo by nucleoside analogues and siRNA. Gastroenterology, 2003,125 : 9-18.
8Kimur K,Kakimi K, Weiland S, et al. Activatied introhepatie antigenpresenting cells inhibit hepatitis B virus replication in the liver of transgenic mice. J Immunol, 2002,169 : 5188-5195.
9Beckebaum S,Cicinnati VR,Dworacki G,et al. Reduction in the circulating pDC1/pDC2 ratio and impaired function of ex vivo-generated DC1 in chronic hepatitis B infection. Clin Immunol, 2002,104 : 138-150.
10Lewin S,Walters T, Locarnini S. Hepatitis B treatment : rational combination chemotherapy based on viral kinetic and animal model studies.Antiviral Res,2002,55 : 381-396.
